Floatz logo

Idarubicine

IDH1 Mutation Myeloid Neoplasms

Northwestern UniversityPhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
95/ 100

Competitive context

30 Active assets in the IDH1 Mutation Myeloid Neoplasms cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 3BBB
Mitoxantrone
First Affiliated Hospital of Zhejiang University
Phase 3BBB
Cladribine
University of Washington
Phase 2BBB
Cyclophosphamide
Prelude Therapeutics
Phase 3BB
METHOTREXATE
St. Jude Children's Research Hospital
Phase 3BB

View all 49 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →